Verapamil


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Supraventricular arrhythmias 120-480 mg/day in 3-4 divided doses. Angina pectoris 120 mg tid or 80 mg tid in patients w/ angina of effort. As modified-release: Up to 480 mg/day. HTN Initial: 240 mg/day in 2-3 divided doses. Max: 480 mg/day. Secondary prophylaxis of MI Modified release: Initial: 360 mg/day in divided doses 1 wk after acute infarction. IV Supraventricular arrhythmias Initial: 5-10 mg via slow inj over 2-3 min then 5 mg via inj over 5-10 min if needed.
Dosage Details
Intravenous
Supraventricular arrhythmias
Adult: Initially, 5-10 mg via slow inj over 2-3 minutes then 5 mg via inj after 5-10 minutes if needed.
Child: ≤1 years 0.1-0.2 mg/kg; 1-15 years 0.1-0.3 mg/kg (Max: 5 mg). All doses to be given over at least 2 minutes, repeat after 30 min if needed.

Oral
Angina pectoris
Adult: 120 mg tid or 80 mg tid in patients w/ angina of effort. As modified-release: Up to 480 mg daily.

Oral
Supraventricular arrhythmias
Adult: 120-480 mg daily in 3-4 divided doses depending on patient's response and severity of the condition.
Child: ≤2 yr 20 mg 2-3 times daily; >2 yr 40-120 mg 2-3 times daily, depending on age and response.

Oral
Hypertension
Adult: Initially, 240 mg daily in 2-3 divided doses. Max: 480 mg daily.
Child: ≤2 yr 20 mg 2-3 times daily; >2 yr 40-120 mg 2-3 times daily, depending on age and response.

Oral
Secondary prophylaxis of myocardial infarction
Adult: Modified release: Initially, 360 mg daily in divided doses 1 wk after acute infarction.
Hepatic Impairment
Oral:
Severe: Reduce dose by up to 60-70%.
Administration
Should be taken with food.
Incompatibility
Y-site: Ampothericin B cholesteryl sulfate complex, nafcillin, ampicillin, oxacillin, albumin, pantoprazole, Na bicarbonate.
Contraindications
Cardiogenic shock, hypotension (systolic pressure <90 mmHg), marked bradycardia, uncompensated heart failure, 2nd- or 3rd-degree AV block (unless pacemaker is fitted), sick-sinus syndrome, severe ventricular dysfunction, atrial flutter or atrial fibrillation and accessory bypass tract (e.g. Wolff-Parkinson-White, Lown-Ganong-Levine syndromes).
Special Precautions
Patient w/ bradycardia or 1st-degree AV block, attenuated neuromuscular transmission, hypertrophic cardiomyopathy. Avoid abrupt withdrawal. Renal and hepatic impairment. Childn. Pregnancy and lactation.
Adverse Reactions
AV block, bradycardia, worsening heart failure, transient asystole, hypotension, dizziness, flushing, fatigue, headache, dyspnoea, peripheral oedema, constipation, nausea, abnormal liver function, skin reactions, gingival hyperplasia, extrapyramidal symptoms. Rarely, gynaecomastia.
Potentially Fatal: Hepatotoxicity.
IV/Parenteral/PO: C
MonitoringParameters
Monitor BP, heart rate, ECG, LFTs (periodically).
Overdosage
Symptoms: Bradycardia, hypotension, conduction abnormalities, hyperglycaemia, hyperkalaemia, metabolic acidosis, renal dysfunction, seizures, impaired conduction, ECG changes, arrhythmias, shock, altered mental status, cardiac arrest. Management: Symptomatic and supportive treatment. Place patient Trendelenburg's position and admin IV fluids. Hypotension may be treated w/ IV Ca salts or vasopressor agent. Bradycardia or fixed 2nd- or 3rd-degree AV block may be treated w/ norepinephrine, IV atropine, isoproterenol, Ca salt or a temporary cardiac pacemaker. Consider endoscopy in cases of large overdoses.
Drug Interactions
May increase plasma level w/ CYP3A4 inhibitors (e.g. erythromycin, ritonavir), cimetidine. May decrease plasma level w/ CYP3A4 inducers (e.g. rifampicin), phenobarbital, sulfinpyrazone. Increased risk of bleeding w/ aspirin. May increase bradycardic and hypotensive effect w/ telithromycin. Increased AV blocking effect w/ clonidine. May increase plasma level of cardiac glycosides (e.g. digoxin, digitoxin), β-blockers (e.g. propranolol, metoprolol), α-blockers (e.g. terazosin, prazosin), immunosuppressants (e.g. sirolimus, ciclosporin, tacrolimus, everolimus), lipid lowering agents (e.g. lovastatin, simvastatin, atorvastatin), colchicines, quinidine, carbamazepine, imipramine, glibenclamide, doxorubicin, midazolam, buspirone, almotriptan, theophylline. May potentiate hypotensive effect w/ diuretics, antihypertensives, vasodilators. May increase neurotoxic effect of lithium.
Food Interaction
Increased plasma levels w/ grapefruit juice. May increase plasma level of alcohol. Decreased plasma levels w/ St John's wort.
Lab Interference
May cause false-positive result w/ urine detection of methadone.
Action
Description: Verapamil inhibits entry of Ca ions into the slow channels or select voltage-sensitive areas of vascular smooth muscle and myocardium during depolarisation. It relaxes coronary vascular smooth muscle and coronary vasodilation, increases myocardial oxygen delivery, and slows automaticity and AV node conduction.
Onset: W/in 1-2 hr (oral); w/in 5 min (IV).
Duration: 6-8 hr (oral); 10-20 min (IV).
Pharmacokinetics:
Absorption: Absorbed from the GI tract approx 90%. Bioavailability: 20-35% (oral). Time to peak plasma concentration: 1-2 hr (oral).
Distribution: Crosses the placenta; enters breast milk. Volume of distribution: 3.89 L/kg. Plasma protein binding: Approx 90%.
Metabolism: Extensively metabolised hepatically to at least 12 metabolites (e.g. norverapamil as primary metabolites).
Excretion: Via urine (70% as metabolites, 3-4% as unchanged drug); faeces (16%). Terminal half-life: 2-8 hr; increases to 4.5-12 hr (after oral repeated dose).
Chemical Structure

Click on icon to see table/diagram/image
Storage
Store between 15-30°C. Protect from light.
MIMS Class
ATC Classification
C08DA01 - verapamil ; Belongs to the class of phenylalkylamine derivative selective calcium-channel blockers with direct cardiac effects. Used in the treatment of cardiovascular diseases.
Disclaimer: This information is independently developed by MIMS based on Verapamil from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
  • Verpamil
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in